Abstract
Molecular Diagnostics Provide Novel Information to Physicians and Patients
With growing levels of technological automation and throughput processing rates, molecular
diagnostics has been recognized as one of the fastest growing markets in the European in vitro
diagnostics (IVD) industry. Its ability to sensitively and distinctly detect the primary cause of
diseases is unprecedented in medicine. These tests seek to supplement or replace traditional
laboratory tests and established standards of care and clinical utility. However, molecular
diagnostics have to undergo clinical tests and trials to demonstrate that the information provided
by them improves the quality of decision-making and patient care by physicians.
This Frost & Sullivan research service provides an overview of and an outlook for the
molecular diagnostics markets in Europe, detailing revenue forecasts by region and providing market
share analyses. The study defines molecular diagnostics to include diagnosis of infectious diseases,
cancer and pharmacogenomics. The information offered by this exhaustive study can prove valuable to
both large and small participants seeking to position themselves in these highly competitive
markets.
Infectious Disease Diagnostics Boost Molecular Diagnostics Revenues in Europe
In 2004, the infectious disease diagnostics segment contributed up to 80.0 per cent to the
European molecular diagnostics markets, indicating high end-user acceptance of them. Cancer and
pharmacogenomic diagnostics generated 10.0 per cent of revenues in 2004. "Cancer diagnostics,
representing an alternative to the conventional testing methods for cancer could, based on feedback
received, introduce tests that are simple, quick, easily accessible and ensure trouble-free
reimbursement, " says the analyst of this research service. "On the other hand,
pharmacogenomics, though still developing, holds immense potential to develop into a lucrative
market as the demand for personalised medicine increases."
New Technologies in Molecular Diagnostics Can Support Point-of-Care Tests
In 2004, the total European molecular diagnostics market generated revenues of $442.0 million
with a growth rate of 10.0 per cent. This is likely to increase in the coming five to six years as
alternative solutions are introduced into the market. "New technologies with the potential to
reduce labour costs and improve turn-around times can provide convenience and portability that
support point-of-care tests, eventually contributing to an increase in market revenues,"
observes the analyst.
Overall, molecular diagnostics, with a clear emphasize on early disease detection, has gained
from successful campaigns across Europe that encourage people to screen for diseases. Consistent
screening helps in reducing negative outcomes arising due to non-diagnosis of conditions. In
addition, while screening for heritable diseases is complex, predisposition testing can throw light
on the hereditary risks involved, thus making screening for early detection crucial. | 
View Cart
